Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.

@article{TorpPedersen2013VernakalantCO,
  title={Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.},
  author={Christian Torp-Pedersen and A. John Camm and Noam N. Butterfield and George D. Dickinson and Gregory N. Beatch},
  journal={International journal of cardiology},
  year={2013},
  volume={166 1},
  pages={147-51}
}
BACKGROUND Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD). METHODS The presence of IHD was extracted from the medical history of patients from four randomized placebo-controlled studies and one open label study. The efficacy analysis included patients with recent onset… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…